Search research articles
Contact Us
Filters
Showing results (341-350 of 381) with videos related to
Page
of 39
Sort By:
Advances in Experimental Medicine and Biology
|
February 23, 1999
Targeted reduction of oxytocin expression provides insights into its physiological roles
W S Young, E Shepard, A C DeVries, et al.
Cancer Research
|
September 24, 1999
Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa)
J Zhao, J Richter, U Wagner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 12, 2002
Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer
Bois A du, W Meier, H J Lück, et al.
British Journal of Cancer
|
July 28, 2012
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
U Wagner, C Marth, R Largillier, et al.
Leukemia
|
May 6, 2014
Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2
E Grundschober, A Hoelbl-Kovacic, N Bhagwat, et al.
Die Rehabilitation
|
January 12, 2008
[Lymphedema in patients with breast cancer--a consensus regarding diagnostics and therapy in patients with postoperative lymphedema after primary breast cancer]
U Seifart, U-S Albert, M-E Heim, et al.
Zentralblatt Fur Gynakologie
|
June 4, 1999
[Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)]
U Wagner, S Köhler, G Prietl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 15, 2001
Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001
U Wagner, S Köhler, S Reinartz, et al.
Gynecologic Oncology
|
January 22, 2005
A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8)
A du Bois, A Belau, U Wagner, et al.
Gynecologic Oncology
|
July 8, 2011
Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group
K Baumann, J Pfisterer, P Wimberger, et al.
Page
of 39
Search research articles
Search
Showing results (341-350 of 381) with videos related to
Sort By:
Page
of 39
Advances in Experimental Medicine and Biology
|
February 23, 1999
Targeted reduction of oxytocin expression provides insights into its physiological roles
W S Young, E Shepard, A C DeVries, et al.
Cancer Research
|
September 24, 1999
Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa)
J Zhao, J Richter, U Wagner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 12, 2002
Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer
Bois A du, W Meier, H J Lück, et al.
British Journal of Cancer
|
July 28, 2012
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
U Wagner, C Marth, R Largillier, et al.
Leukemia
|
May 6, 2014
Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2
E Grundschober, A Hoelbl-Kovacic, N Bhagwat, et al.
Die Rehabilitation
|
January 12, 2008
[Lymphedema in patients with breast cancer--a consensus regarding diagnostics and therapy in patients with postoperative lymphedema after primary breast cancer]
U Seifart, U-S Albert, M-E Heim, et al.
Zentralblatt Fur Gynakologie
|
June 4, 1999
[Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)]
U Wagner, S Köhler, G Prietl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 15, 2001
Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001
U Wagner, S Köhler, S Reinartz, et al.
Gynecologic Oncology
|
January 22, 2005
A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8)
A du Bois, A Belau, U Wagner, et al.
Gynecologic Oncology
|
July 8, 2011
Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group
K Baumann, J Pfisterer, P Wimberger, et al.
Page
of 39